NeuClone, Serum India Sign Global Licensing Deal For 10 Biosimilars
This article was originally published in PharmAsia News
The Serum Institute of India and NeuClone have signed a licensing agreement for the Australia-based biotech to combine its cell-line development platform with the India firm's biologics expertise to produce 10 biosimilar monoclonal antibodies.
You may also be interested in...
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.